Jeanne E Hendrickson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6189550/publications.pdf

Version: 2024-02-01

		76326	95266
174	5,485	40	68
papers	citations	h-index	g-index
178	178	178	3829
170	170	170	3029
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfusion and Apheresis Science, 2022, 61, 103304.	1.0	2
2	Donor genetic and nongenetic factors affecting red blood cell transfusion effectiveness. JCI Insight, 2022, 7, .	5.0	29
3	Innate and Adaptive Immunity to Transfused Allogeneic RBCs in Mice Requires MyD88. Journal of Immunology, 2022, 208, 991-997.	0.8	7
4	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine, 2022, 182, 115.	5.1	63
5	Autologous hematopoietic stem cell product contaminated with <i>Salmonella</i> due to occult salmonellosis in an asymptomatic donor. Journal of Clinical Apheresis, 2022, 37, 316-319.	1.3	3
6	International guidelines regarding the role of IVIG in the management of Rh†and ABOâ€mediated haemolytic disease of the newborn. British Journal of Haematology, 2022, , .	2.5	6
7	The Recipient Epidemiology and Donor Evaluation ⟨scp⟩Studyâ€Nâ€Pediatric⟨ scp⟩ (⟨scp⟩REDSâ€Nâ€P⟨ scp⟩): research program striving to improve blood donor safety and optimize transfusion outcomes across the lifespan. Transfusion, 2022, 62, 982-999.	: A 1.6	16
8	Clodronate inhibits alloimmunization against distinct red blood cell alloantigens in mice. Transfusion, 2022, 62, 948-953.	1.6	10
9	Parasite burden and red blood cell exchange transfusion for babesiosis. Journal of Clinical Apheresis, 2021, 36, 127-134.	1.3	10
10	Factor V activity in apheresis platelets: Implications for management of FV deficiency. Transfusion, 2021, 61, 405-409.	1.6	3
11	Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood, 2021, 137, 969-976.	1.4	46
12	Pediatric Hemovigilance and Adverse Transfusion Reactions. Clinics in Laboratory Medicine, 2021, 41, 51-67.	1.4	2
13	Marginal zone B cells mediate a CD4 T-cell–dependent extrafollicular antibody response following RBC transfusion in mice. Blood, 2021, 138, 706-721.	1.4	34
14	Transfusion practices in a large cohort of hospitalized children. Transfusion, 2021, 61, 2042-2053.	1.6	19
15	Optimization of repeat plerixafor dosing for autologous peripheral blood stem-cell collection. Transfusion and Apheresis Science, 2021, 60, 103069.	1.0	1
16	The lysophospholipidâ€binding molecule <scp>CD1D</scp> is not required for the alloimmunization response to fresh or stored <scp>RBCs</scp> in mice despite <scp>RBC</scp> storage driving alterations in lysophospholipids. Transfusion, 2021, 61, 2169-2178.	1.6	8
17	Complement Plays a Critical Role in Inflammation-Induced Immunoprophylaxis Failure in Mice. Frontiers in Immunology, 2021, 12, 704072.	4.8	5
18	Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease. EJHaem, 2021, 2, 700-710.	1.0	6

#	Article	IF	CITATIONS
19	Transfusion Practices in Pediatric Cardiac Surgery Requiring Cardiopulmonary Bypass: A Secondary Analysis of a Clinical Database. Pediatric Critical Care Medicine, 2021, 22, 978-987.	0.5	14
20	Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS ONE, 2021, 16, e0254453.	2.5	27
21	Transfusion practices for pediatric oncology and hematopoietic stem cell transplantation patients: Data from the <scp>National Heart Lung and Blood Institute Recipient Epidemiology and Donor Evaluation Studyâ€III (REDSâ€III)</scp> . Transfusion, 2021, 61, 2589-2600.	1.6	10
22	Variation in Neonatal Transfusion Practice. Journal of Pediatrics, 2021, 235, 92-99.e4.	1.8	45
23	Development of anti-Jk3 associated with silenced Kidd antigen expression and a novel single nucleotide variant of the <i>JK</i> gene. Immunohematology, 2021, 37, 109-112.	0.2	0
24	Therapeutic plasma exchange for peripheral neuropathy associated with trisulfated heparan disaccharide IgM antibodies: A case series of 17 patients. Journal of Clinical Apheresis, 2021, , .	1.3	4
25	Potential Implications of a Type 1 Interferon Gene Signature on COVID-19 Severity and Chronic Inflammation in Sickle Cell Disease. Frontiers in Medicine, 2021, 8, 679030.	2.6	0
26	<scp>RBC</scp> alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?. Transfusion, 2021, 61, 3283-3285.	1.6	2
27	Management of hemolytic transfusion reactions. Hematology American Society of Hematology Education Program, 2021, 2021, 704-709.	2.5	6
28	Recipient factors influencing red blood cell alloimmunization. ISBT Science Series, 2020, 15, 194-200.	1.1	2
29	Human leukocyte antigen (HLA) class I antibodies and transfusion support in paediatric HLAâ€matched haematopoietic cell transplant for sickle cell disease. British Journal of Haematology, 2020, 189, 162-170.	2.5	6
30	<scp>NTâ€proBNP</scp> levels in the identification and classification of pulmonary transfusion reactions. Transfusion, 2020, 60, 2548-2556.	1.6	4
31	Immunohematologic aspects of alloimmunization and alloantibody detection: A focus on pregnancy and hemolytic disease of the fetus and newborn. Transfusion and Apheresis Science, 2020, 59, 102946.	1.0	12
32	COVID-19 and the Coombs test. Blood, 2020, 136, 655-656.	1.4	7
33	Preventing transfusionâ€associated graftâ€versusâ€host disease with blood component irradiation: indispensable guidance for a deadly disorder. British Journal of Haematology, 2020, 191, 653-657.	2.5	11
34	The impact of pre-existing HLA and red blood cell antibodies on transfusion support and engraftment in sickle cell disease after nonmyeloablative hematopoietic stem cell transplantation from HLA-matched sibling donors: A prospective, single-center, observational study. EClinicalMedicine, 2020, 24, 100432.	7.1	8
35	Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances, 2020, 4, 3814-3821.	5.2	7
36	Investigation of increased platelet alloimmunization screening in the era of pathogenâ€reduced platelets treated with psoralen/UV light. Transfusion, 2020, 60, 650-651.	1.6	3

#	Article	IF	CITATIONS
37	Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica, 2020, 105, 539-544.	3.5	44
38	Red cell exchange for patients with sickle cell disease: an international survey of current practices. Transfusion, 2020, 60, 1424-1433.	1.6	10
39	The evanescence and persistence of RBC alloantibodies in blood donors. Transfusion, 2020, 60, 831-839.	1.6	12
40	Passive anti acquired in the setting of Rh immune globulin administration following Rh mismatched apheresis platelet transfusion: A case series. Journal of Clinical Apheresis, 2020, 35, 224-226.	1.3	1
41	Application of PLASMIC score in prediction of ADAMTS13 deficiency in a pediatric case of acquired thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2020, 35, 140-141.	1.3	3
42	Characterization of circulating and cultured Tfh-like cells in sickle cell disease in relation to red blood cell alloimmunization status. Transfusion and Apheresis Science, 2020, 59, 102778.	1.0	6
43	Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review of Hematology, 2020, 13, 489-499.	2.2	24
44	Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura. Blood Advances, 2020, 4, 539-545.	5.2	11
45	American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Advances, 2020, 4, 327-355.	5.2	241
46	Use of Convalescent Plasma Therapy in Severe Coronavirus Disease 2019: The Yale-New Haven Health System Experience. Blood, 2020, 136, 39-40.	1.4	2
47	Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura. Blood, 2020, 136, 18-19.	1.4	2
48	Poly(I:C) causes failure of immunoprophylaxis to red blood cells expressing the KEL glycoprotein in mice. Blood, 2020, 135, 1983-1993.	1.4	6
49	Red blood cell alloimmunization and sickle cell disease: a narrative review on antibody induction. Annals of Blood, 2020, 5, 33-33.	0.4	8
50	Co-Culture of Acinetobacter calcoaceticus-baumannii complex and Staphylococcus saprophyticus Supports Simple Point Contamination Model in Recent Cases of Transfusion-Related Sepsis. American Journal of Clinical Pathology, 2020, 154, S14-S14.	0.7	0
51	Optimization of Plerixafor Utilization Based on Peripheral Blood CD34+ Count for Autologous Peripheral Blood Stem-Cell Collection. Blood, 2020, 136, 41-41.	1.4	0
52	Type I Interferon Gene Signature in Peripheral Blood Mononuclear Cells of Sickle Cell Disease Patients and a Connection to RBC Alloimmunization. Blood, 2020, 136, 26-27.	1.4	0
53	Type 1 IFN signaling critically regulates influenzaâ€induced alloimmunization to transfused KEL RBCs in a murine model. Transfusion, 2019, 59, 3243-3252.	1.6	15
54	TRIX with treats: the considerable safety benefits of a transfusion medicine registry. Transfusion, 2019, 59, 2489-2492.	1.6	12

#	Article	IF	CITATIONS
55	A murine neonatal model of necrotizing enterocolitis caused by anemia and red blood cell transfusions. Nature Communications, 2019, 10, 3494.	12.8	74
56	Red blood cell alloimmunization is associated with lower expression of Fcl^3R1 on monocyte subsets in patients with sickle cell disease. Transfusion, 2019, 59, 3219-3227.	1.6	7
57	Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case. Laboratory Medicine, 2019, 50, 313-319.	1.2	1
58	Tollâ€like receptor SNPs and sickle cell disease: a PRRfect storm for RBC alloimmunization. British Journal of Haematology, 2019, 186, 803-804.	2.5	0
59	Fatal acute hemolytic transfusion reaction due to antiâ€B from a platelet apheresis unit stored in platelet additive solution. Transfusion, 2019, 59, 1911-1915.	1.6	20
60	Microbial pathogen primary sequence inversely correlates with blood group antigen immunogenicity. Transfusion, 2019, 59, 1651-1656.	1.6	4
61	Transfusion-related red blood cell alloantibodies: induction and consequences. Blood, 2019, 133, 1821-1830.	1.4	116
62	Red blood cell alloimmunization and delayed hemolytic transfusion reactions in patients with sickle cell disease. Transfusion Clinique Et Biologique, 2019, 26, 112-115.	0.4	20
63	Mechanisms of alloimmunization in sickle cell disease. Current Opinion in Hematology, 2019, 26, 434-441.	2.5	13
64	Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Studyâ€III (REDSâ€III). Transfusion, 2019, 59, 217-225.	1.6	30
65	Increased Expression of Type 1 Interferon Stimulated Genes in Sickle Cell Disease and a Potential Association with RBC Alloimmunization. Blood, 2019, 134, 716-716.	1.4	0
66	Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types. Blood, 2019, 134, 1028-1028.	1.4	0
67	The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors. Blood, 2019, 134, 2452-2452.	1.4	0
68	Transfused platelets enhance alloimmune responses to transfused KEL-expressing red blood cells in a murine model. Blood Transfusion, 2019, 17, 368-377.	0.4	1
69	9 Examining the Correlation Between Microbial Pathogen Sequence Structure and Blood Group Antigen Immunogenicity. American Journal of Clinical Pathology, 2018, 149, S167-S168.	0.7	0
70	Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leukemia and Lymphoma, 2018, 59, 2723-2726.	1.3	16
71	Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (<scp>REDS</scp> â€ <scp>lll</scp>) database. British Journal of Haematology, 2018, 181, 672-681.	2.5	85
72	A patient with oxaliplatin immune-induced syndrome (OIIS) who also developed leucovorin and palonosetron-associated thrombocytopenia. Hematology, 2018, 23, 429-432.	1.5	5

#	Article	IF	CITATIONS
73	A novel association between high red blood cell alloimmunization rates and hereditary hemorrhagic telangiectasia. Transfusion, 2018, 58, 775-780.	1.6	5
74	A multicentre study investigating vital sign changes occurring in complicated and uncomplicated transfusions. Vox Sanguinis, 2018, 113, 160-169.	1.5	12
75	Contemporary Risk Factors and Outcomes of Transfusion-Associated Circulatory Overload*. Critical Care Medicine, 2018, 46, 577-585.	0.9	48
76	Red blood cell alloimmunisation: induction of immunity and potential mitigation strategies. ISBT Science Series, 2018, 13, 105-111.	1.1	4
77	Transfusion Support of the Patient with Sickle Cell Disease Undergoing Transplantation. , 2018, , 111-136.		1
78	Autoimmunity, Autonomic Neuropathy, and the HPV Vaccination: A Vulnerable Subpopulation. Clinical Pediatrics, 2018, 57, 603-606.	0.8	15
79	Delayed haemolytic and serologic transfusion reactions. Current Opinion in Hematology, 2018, 25, 459-467.	2.5	22
80	Autonomic dysfunction and HPV immunization: an overview. Immunologic Research, 2018, 66, 744-754.	2.9	38
81	Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion. Frontiers in Immunology, 2018, 9, 2516.	4.8	31
82	Rhesus pieces: genotype matching of RBCs. Blood, 2018, 132, 1091-1093.	1.4	4
83	Antibody-mediated immune suppression by antigen modulation is antigen-specific. Blood Advances, 2018, 2, 2986-3000.	5.2	31
84	Very low rate of antiâ€D development in male, primarily immunocompetent patients transfused with Dâ€mismatched platelets. Transfusion, 2018, 58, 1568-1569.	1.6	4
85	Complement Component 3 Negatively Regulates Antibody Response by Modulation of Red Blood Cell Antigen. Frontiers in Immunology, 2018, 9, 676.	4.8	30
86	1 Type I Interferon Is Necessary and Sufficient for Alloimmunization to Transfused KEL-Expressing RBCs in Mice. American Journal of Clinical Pathology, 2018, 149, S163-S163.	0.7	0
87	Complement serves as a switch between CD4+ T cell–independent and –dependent RBC antibody responses. JCI Insight, 2018, 3, .	5.0	40
88	Cost Effectiveness of Rituximab As Adjunctive Therapy in Reducing Apheresis Procedures and Hospital Length of Stay in Relapsed Thrombotic Thrombocytopenic Purpura. Blood, 2018, 132, 3814-3814.	1.4	2
89	Influenza Infection Induces RBC Alloimmunization By a Type 1 Interferon Dependent Mechanism. Blood, 2018, 132, 743-743.	1.4	0
90	HLA Class I Alloimmunization and Platelet Transfusion Support in HLA-Identical Bone Marrow Transplant for Sickle Cell Disease: A Sickle Transplant Alliance for Research Study. Blood, 2018, 132, 3816-3816.	1.4	O

#	Article	IF	Citations
91	Elevated Levels of CD64 MFI on Monocyte Subsets Are Associated with a History of Stroke in Sickle Cell Disease. Blood, 2018, 132, 1093-1093.	1.4	2
92	Antigen Density Dictates Immune Responsiveness following Red Blood Cell Transfusion. Journal of Immunology, 2017, 198, 2671-2680.	0.8	54
93	Type I IFN Is Necessary and Sufficient for Inflammation-Induced Red Blood Cell Alloimmunization in Mice. Journal of Immunology, 2017, 199, 1041-1050.	0.8	56
94	The impact of vaccination on <scp>RBC</scp> alloimmunization in a murine model. Vox Sanguinis, 2017, 112, 598-600.	1.5	1
95	2016 proceedings of the National Heart, Lung, and Blood Institute's scientific priorities in pediatric transfusion medicine. Transfusion, 2017, 57, 1568-1581.	1.6	20
96	Irradiation of Red Blood Cells and Alloimmunization. Laboratory Medicine, 2017, 48, 172-177.	1.2	7
97	Limitations of a scoring model to predict thrombotic thrombocytopaenic purpura. Vox Sanguinis, 2017, 112, 185-186.	1.5	1
98	A novel network analysis tool to identify relationships between disease states and risks for red blood cell alloimmunization. Vox Sanguinis, 2017, 112, 469-472.	1.5	12
99	B cells require Type 1 interferon to produce alloantibodies to transfused KELâ€expressing red blood cells in mice. Transfusion, 2017, 57, 2595-2608.	1.6	32
100	Preanalytical errors in transfusion medicine: Reply to "74-year-old female with new monoclonal protein on serum immunofixation electrophoresis― Clinical Biochemistry, 2017, 50, 1334-1335.	1.9	0
101	Bortezomib decreases the magnitude of a primary humoral immune response to transfused red blood cells in a murine model. Transfusion, 2017, 57, 82-92.	1.6	6
102	Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. Transfusion, 2017, 57, 289-295.	1.6	19
103	CD4 Depletion or CD40L Blockade Results in Antigen-Specific Tolerance in a Red Blood Cell Alloimmunization Model. Frontiers in Immunology, 2017, 8, 907.	4.8	18
104	Innate B-1 B Cells Are Not Enriched in Red Blood Cell Autoimmune Mice: Importance of B Cell Receptor Transgenic Selection. Frontiers in Immunology, 2017, 8, 1366.	4.8	4
105	Complex regional pain syndrome and dysautonomia in a 14â€yearâ€old girl responsive to therapeutic plasma exchange. Journal of Clinical Apheresis, 2016, 31, 368-374.	1.3	21
106	Erythrophagocytosis by plasmacytoid dendritic cells and monocytes is enhanced during inflammation. Transfusion, 2016, 56, 905-916.	1.6	37
107	Interleukin-6 receptor-alpha signaling drives anti-RBC alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. Haematologica, 2016, 101, e440-e444.	3.5	30
108	Antigen modulation as a potential mechanism of anti-KEL immunoprophylaxis in mice. Blood, 2016, 128, 3159-3168.	1.4	43

#	Article	IF	Citations
109	Understanding red blood cell alloimmunization triggers. Hematology American Society of Hematology Education Program, 2016, 2016, 446-451.	2.5	72
110	Red blood cell alloimmunization: new findings at the bench and new recommendations for the bedside. Current Opinion in Hematology, 2016, 23, 543-549.	2.5	23
111	Bridging channel dendritic cells induce immunity to transfused red blood cells. Journal of Experimental Medicine, 2016, 213, 887-896.	8.5	89
112	Transfusion Medicine. Hematology/Oncology Clinics of North America, 2016, 30, xiii-xiv.	2.2	0
113	Red Blood Cell Antibodies in Hematology/Oncology Patients. Hematology/Oncology Clinics of North America, 2016, 30, 635-651.	2.2	35
114	The Nlrp3 Inflammasome Does Not Regulate Alloimmunization to Transfused Red Blood Cells in Mice. EBioMedicine, 2016, 9, 77-86.	6.1	20
115	Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. Transfusion, 2016, 56, 107-114.	1.6	111
116	Human papilloma virus vaccination and dysautonomia: Considerations for autoantibody evaluation and HLA typing. Vaccine, 2016, 34, 4468.	3.8	22
117	CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood, 2016, 127, 1823-1827.	1.4	45
118	Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion, 2016, 56, 2587-2596.	1.6	103
119	Platelet and plasma transfusions for infants and children. , 2016, , 542-548.		0
120	Leukoreduced red blood cell transfusions do not induce platelet glycoprotein antibodies in patients with sickle cell disease. Transfusion, 2016, 56, 2267-2273.	1.6	1
121	Clinically significant antiâ€∢scp>KEL RBC alloantibodies are transferred by breast milk in a murine model. Vox Sanguinis, 2016, 111, 79-87.	1.5	15
122	Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations. Transfusion Medicine Reviews, 2016, 30, 159-164.	2.0	85
123	Riboflavinâ€ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells. Transfusion, 2016, 56, 863-872.	1.6	10
124	Chronic inflammatory autoimmune disorders are a risk factor for red blood cell alloimmunization. British Journal of Haematology, 2016, 174, 483-485.	2.5	50
125	Determination of Red Blood Cell Alloimmunization Rates in Transfused Patients with Hematologic and Oncologic Malignancies. Blood, 2016, 128, 1463-1463.	1.4	5
126	Anti-KEL sera prevents alloimmunization to transfused KEL RBCs in a murine model. Haematologica, 2015, 100, e394-e397.	3.5	42

#	Article	IF	CITATIONS
127	Variation in vital signs resulting from blood component administration in adults. Transfusion, 2015, 55, 1866-1871.	1.6	16
128	Routine nonâ€ABO blood group antigen genotyping in sickle cell disease: the new frontier in pretransfusion testing?. Transfusion, 2015, 55, 1374-1377.	1.6	8
129	Measuring the influence of blood component infusion rate on recipient vital signs. Vox Sanguinis, 2015, 109, 353-358.	1.5	8
130	Immunophenotypic parameters and <scp>RBC</scp> alloimmunization in children with sickle cell disease on chronic transfusion. American Journal of Hematology, 2015, 90, 1135-1141.	4.1	66
131	Red blood cell transfusions are associated with <scp>HLA</scp> class I but not H‥ alloantibodies in children with sickle cell disease. British Journal of Haematology, 2015, 170, 247-256.	2.5	21
132	Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. British Journal of Haematology, 2015, 169, 574-583.	2.5	36
133	Anti-RhD Mediates Loss of RhD Antigen Following Anti-RhD Infusion. Blood, 2015, 126, 3570-3570.	1.4	3
134	Antigen Density Impacts RBC Survival and Antigen Modulation Following Incompatible RBC Transfusion. Blood, 2015, 126, 2350-2350.	1.4	0
135	DOCK8-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood, 2015, 126, 658-658.	1.4	0
136	North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia. Blood, 2015, 126, 1138-1138.	1.4	4
137	A Novel Network Analysis Tool to Identify Relationships Between Disease States and Risk for RBC Alloimmunization. Blood, 2015, 126, 2349-2349.	1.4	0
138	Factors Influencing RBC Alloimmunization: Lessons Learned from Murine Models. Transfusion Medicine and Hemotherapy, 2014, 41, 406-419.	1.6	71
139	Strainâ€specific red blood cell storage, metabolism, and eicosanoid generation in a mouse model. Transfusion, 2014, 54, 137-148.	1.6	87
140	Antibody-Mediated Immune Suppression of Erythrocyte Alloimmunization Can Occur Independently from Red Cell Clearance or Epitope Masking in a Murine Model. Journal of Immunology, 2014, 193, 2902-2910.	0.8	41
141	Transfusion of murine red blood cells expressing the human <scp>KEL</scp> glycoprotein induces clinically significant alloantibodies. Transfusion, 2014, 54, 179-189.	1.6	61
142	Red Blood Cell Alloimmunization Mitigation Strategies. Transfusion Medicine Reviews, 2014, 28, 137-144.	2.0	53
143	The ethics of a proposed study of hematopoietic stem cell transplant for children with "less severe― sickle cell disease. Blood, 2014, 124, 861-866.	1.4	30
144	Coagulopathy Predicts Mortality in Pediatric Patients with Traumatic Brain Injury. Blood, 2014, 124, 2891-2891.	1.4	2

#	Article	IF	CITATIONS
145	CD8+ T Cells Mediate Antibody-Independent Platelet Clearance Following Transfusion. Blood, 2014, 124, 596-596.	1.4	O
146	Reticuloendothelial Saturation Dictates the Development of RBC Resistance to Antibody-Mediated Clearance Following Incompatible Transfusion. Blood, 2014, 124, 1559-1559.	1.4	0
147	Chronic Inflammatory Autoimmune Disorders Are a Risk Factor for Blood Group Alloimmunization in Transfused Patients. Blood, 2014, 124, 4294-4294.	1.4	0
148	NLRP10-Deficient Mice Reveal a Crucial Role for Dendritic Cell Activity in the Initiation of the Allogeneic Response to Transfused Red Blood Cells. Blood, 2014, 124, 4113-4113.	1.4	0
149	Frequency of glucoseâ€6â€phosphate dehydrogenase–deficient red blood cell units in a metropolitan transfusion service. Transfusion, 2013, 53, 606-611.	1.6	43
150	Antigen Modulation Confers Protection to Red Blood Cells from Antibody through Fcl^3 Receptor Ligation. Journal of Immunology, 2013, 191, 5013-5025.	0.8	61
151	Alloantibodies to a paternally derived RBC KEL antigen lead to hemolytic disease of the fetus/newborn in a murine model. Blood, 2013, 122, 1494-1504.	1.4	47
152	A novel role for C3 in antibody-induced red blood cell clearance and antigen modulation. Blood, 2013, 122, 1793-1801.	1.4	62
153	Transfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs. Blood, 2012, 119, 1566-1569.	1.4	75
154	Alloimmunization to transfused HOD red blood cells is not increased in mice with sickle cell disease. Transfusion, 2012, 52, 231-240.	1.6	23
155	Implementation of a pediatric trauma massive transfusion protocol: one institution's experience. Transfusion, 2012, 52, 1228-1236.	1.6	123
156	Generation of transgenic mice with antithetical KEL1 and KEL2 human blood group antigens on red blood cells. Transfusion, 2012, 52, 2620-2630.	1.6	47
157	Coagulopathy is Prevalent and Associated with Adverse Outcomes in Transfused Pediatric Trauma Patients. Journal of Pediatrics, 2012, 160, 204-209.e3.	1.8	100
158	Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non–transferrin-bound iron. Blood, 2011, 118, 6675-6682.	1.4	267
159	Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity. Transfusion, 2011, 51, 2445-2454.	1.6	31
160	Transfusion of fresh murine red blood cells reverses adverse effects of older stored red blood cells. Transfusion, 2011, 51, 2695-2702.	1.6	36
161	Central T Cell Tolerance and Peripheral B Cell Tolerance for An RBC Autoantigen Are Incomplete in Healthy Mice; Implications for AIHA Pathogenesis. Blood, 2011, 118, 693-693.	1.4	5
162	IMMUNOHEMATOLOGY: Storage of murine red blood cells enhances alloantibody responses to an erythroidâ€specific model antigen. Transfusion, 2010, 50, 642-648.	1.6	71

#	Article	IF	CITATIONS
163	Regulation of primary alloantibody response through antecedent exposure to a microbial T-cell epitope. Blood, 2010, 115, 3989-3996.	1.4	61
164	Use of mouse models to study the mechanisms and consequences of RBC clearance. Vox Sanguinis, 2010, 99, 99-111.	1.5	33
165	Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation. Blood, 2010, 115, 4284-4292.	1.4	449
166	Noninfectious Serious Hazards of Transfusion. Anesthesia and Analgesia, 2009, 108, 759-769.	2.2	360
167	A novel mouse model of red blood cell storage and posttransfusion in vivo survival. Transfusion, 2009, 49, 1546-1553.	1.6	106
168	The spleen plays a central role in primary humoral alloimmunization to transfused mHEL red blood cells. Transfusion, 2009, 49, 1678-1684.	1.6	35
169	Leukoreduction Decreases Alloimmunogenicity of Transfused Murine HOD RBCs Blood, 2009, 114, 640-640.	1.4	1
170	Discrete Tollâ€like receptor agonists have differential effects on alloimmunization to transfused red blood cells. Transfusion, 2008, 48, 1869-1877.	1.6	50
171	A Novel Model of Autoimmunity to Self Red Blood Cell Antigens. Blood, 2008, 112, 3461-3461.	1.4	0
172	Inflammation enhances consumption and presentation of transfused RBC antigens by dendritic cells. Blood, 2007, 110, 2736-2743.	1.4	126
173	Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells. Transfusion, 2006, 46, 1526-1536.	1.6	161
174	Host Inflammation Increases Alloimmunization to Transfused Red Blood Cells Blood, 2005, 106, 1887-1887.	1.4	0